Imatinib Basics (Imatinib)

Imatinib targets specific tyrosine kinases involved in malignant cell growth, making it useful for several hematologic and solid‑tumor indications.

• Chronic Myeloid Leukemia (CML): reduces abnormal white‑blood‑cell proliferation and improves long‑term survival.
• Gastrointestinal Stromal Tumor (GIST): inhibits tumor growth and delays disease progression.
• Philadelphia chromosome‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): provides targeted therapy for this specific leukemia subtype.

• Imatinib binds to the ATP‑binding site of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing phosphorylation and downstream signaling. This blockade halts uncontrolled cellular proliferation and induces apoptosis in malignant cells that rely on these kinases for growth.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Edema: swelling of the hands, feet, or face.
• Muscle cramps: painful tightening of skeletal muscles.
• Fatigue: persistent tiredness.
• Diarrhea: loose stools.
• Rash: skin irritation or redness.

Serious or Rare Side Effects

• Severe neutropenia: dangerously low white‑blood‑cell count.
• Hepatotoxicity: liver enzyme elevations or liver injury.
• Cardiac failure: reduced heart pumping ability.
• Pulmonary hypertension: high blood pressure in lung arteries.
• Stevens‑Johnson syndrome: severe skin reaction.
• Hemorrhage: abnormal bleeding events.

Patients should be monitored closely for safety concerns before and during therapy.

• Blood count monitoring: perform regular CBC to detect cytopenias.
• Liver function assessment: check ALT/AST levels periodically.
• Cardiac evaluation: assess for signs of heart failure or hypertension.
• Pregnancy avoidance: drug is contraindicated in pregnancy due to unknown risks.
• Drug interaction review: evaluate concomitant medications for CYP3A4 effects.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib may interact with several medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib levels.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
• Antacids containing aluminum or magnesium: can lower absorption.
• QT‑prolonging agents (e.g., sotalol, quinidine): increase risk of cardiac arrhythmias.
• Warfarin: may enhance anticoagulant effect.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly increase exposure.
• CYP3A4 substrates (e.g., statins): monitor for altered lipid‑lowering effect.
• Diuretics (e.g., furosemide): watch for electrolyte disturbances.
• NSAIDs: increased risk of gastrointestinal bleeding.
• Vaccines (live attenuated): potential reduced efficacy.